Phase 1 Randomized, Double-Blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Repeat Administration (7 Days) of Ascending Oral Doses of Bendavia in Healthy Volunteers
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Number of adverse events observed with and without Bendavia
研究概览
简要总结
The purpose of this study is to assess the study medication blood levels after administration of a repeat oral capsules (one capsule each day for seven days) of Bendavia at one of two dose levels. The effects of Bendavia on the volunteers will also be assessed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult males or females aged between 18 and 65 years of age with signed informed consent.
- •Women who are not post-menopausal (without menstrual bleed for >24 months) or surgically sterile must have a negative serum pregnancy test at screening and within 24 hours of treatment with understanding (through informed consent process) to not become pregnant over the duration of the study and must agree to employ an effective form of birth control for the duration of the study.
- •Acceptable forms of birth control are: double-barrier contraceptives (condom, diaphragm with spermicide) or interuterine device (IUD) 1 week prior to and at least 30 days post treatment even if hormonal contraceptives are used.
排除标准
- •Serum sodium level below the lower limit of the site's clinical laboratory normal range at the study qualification visit,
- •Clinically significant laboratory abnormalities as determined by the Principal Investigator at laboratory screening
- •Creatinine clearance calculated by the Cockcroft and Gault method calculated to be <90 mL/min for males and <80 mL/min for females
- •Clinically significant abnormalities on physical examination,
- •Body weight less than 60 kg or greater than 80 kg or a body mass index of less than 18 kg/m2 or greater than 32 kg/m2,
- •Any disease or condition that might compromise the cardiovascular, hematological, renal, hepatic, pulmonary (including chronic asthma), endocrine (e.g., diabetes), central nervous, or gastrointestinal (including an ulcer) systems,
- •History of seizures or history of epilepsy,
- •History of serious (Principal Investigator judgment) mental illness,
- •Participant in any research involving investigational product within 30 days before planned date of drug administration,
- •Positive serology for HIV 1, HIV 2, HBsAg, or hepatitis C virus (HCV),
- •Fever greater than 37.5°C at the time of planned dosing,
- •Suspicion, or recent history, of alcohol or substance abuse,
- •Donated blood or blood products within the past 30 days,
- •Women who are pregnant or breastfeeding,
- •Employee or family member of an employee of the investigational site,
- •Subjects who currently smoke cigarettes, cigars, pipes or chew tobacco products or who have used any tobacco product in the 30 days prior to screening,
- •Subjects who are either unwilling to agree to refrain from use or found to be using:
- •Alcohol, caffeine, xanthine-containing food or beverages, nicotine products and over-the-counter medications with the exception of Tylenol from 24 hours prior to dosing and throughout the confinement periods
- •Prescription medications from 14 days prior to and 7 days post treatment (excluding hormonal contraceptives)
- •Hormonal contraceptives without concomitant use of double-barrier contraceptives (condom, diaphragm with spermicide) for a period of 7 days prior to and 30 days post treatment
- •Subjects having previous exposure to Bendavia
研究组 & 干预措施
Bendavia 10mg
Bendavia capsule, 10mg, once daily for 7 days
干预措施: Bendavia 10mg (Drug)
Bendavia 10mg
Bendavia capsule, 10mg, once daily for 7 days
干预措施: Placebo (Drug)
Placebo
Placebo (matching), once daily for 7 days
干预措施: Placebo (Drug)
Bendavia 50mg
Bendavia capsule, 50mg, once daily for 7 days
干预措施: Bendavia 50mg (Drug)
Bendavia 50mg
Bendavia capsule, 50mg, once daily for 7 days
干预措施: Placebo (Drug)
结局指标
主要结局
Number of adverse events observed with and without Bendavia
时间窗: From time of study drug administration to End of Study (Day 10)
Adverse events will be tabulated by treatment group. No statistical analysis will be performed.
Mean peak plasma concentration (Cmax) of Bendavia (ng/ml) on Day 1 in each cohort.
时间窗: Immediately prior to dosing (Day 1, 0hr) to 24 hours post-dose
Blood drawn at pre-dose (immediately prior to study drug ingestion) and post-dose at +0.5, +1, +1.5, +2, +2.5, +3, +3.5, +4, +5, +6, +8, +12, +18 hours and pre-Day2-dose (approximately 24 hours post-Day1-dose) will be assessed for Bendavia plasma concentrations. Mean Cmax is defined as the mean of maximum concentration reported for each subject by cohort.
Mean peak plasma concentration (Cmax) of Bendavia (ng/ml) on Day 7 in each cohort.
时间窗: Immediately prior to dosing (Day 7, 0hr) to 24 hours post-dose
Blood drawn at Day 7 pre-dose (immediately prior to study drug ingestion) and post-dose at +0.5, +1, +1.5, +2, +2.5, +3, +3.5, +4, +5, +6, +8, +12, +18 and +24 hours will be assessed for Bendavia plasma concentrations. Mean Cmax is defined as the mean of maximum concentration reported for each subject by cohort.
Mean time to peak plasma concentration (Tmax) of Bendavia (hr) on Day 1 in each cohort.
时间窗: Immediately prior to dosing (Day 1, 0hr) to 24 hours post-dose
Blood drawn at Day 1 pre-dose (immediately prior to study drug ingestion) and post-dose at +0.5, +1, +1.5, +2, +2.5, +3, +3.5, +4, +5, +6, +8, +12, +18 hours and pre-Day2-dose (approximately 24 hours post-Day1-dose) will be assessed for Bendavia plasma concentrations. Mean Tmax is defined as the mean of the time of maximum concentration reported for each subject by cohort.
Mean time to peak plasma concentration (Tmax) of Bendavia (hr) on Day 7 in each cohort.
时间窗: Immediately prior to dosing (Day 7, 0hr) to 24 hours post-dose
Blood drawn at Day 7 pre-dose (immediately prior to study drug ingestion) and post-dose at +0.5, +1, +1.5, +2, +2.5, +3, +3.5, +4, +5, +6, +8, +12, +18 and +24 hours will be assessed for Bendavia plasma concentrations. Mean Tmax is defined as the mean of the time of maximum concentration reported for each subject by cohort.
Mean Area Under the Curve (AUC) from 0-24 hours on Day 1 for Bendavia (hr.ng/ml) in the time from dosing to 24 hours post-dose in each cohort.
时间窗: Immediately prior to dosing (Day 1, 0hr) to 24 hours post-dose
Blood drawn at Day 1 pre-dose (immediately prior to study drug ingestion) and post-dose at +0.5, +1, +1.5, +2, +2.5, +3, +3.5, +4, +5, +6, +8, +12 and +18 hours and pre-D2-dose (approximately 24 hours post-D1-dose) will be assessed for Bendavia plasma concentrations. AUC (0-24hr) will be calculated using validated pharmacokinetic analysis software and mean AUC for Bendavia is defined as the mean of AUC (0-24hr) reported for each subject by cohort
Mean Area Under the Curve (AUC) from 0-24 hours on Day 7 for Bendavia (hr.ng/ml) in the time from dosing to 24 hours post-dose in each cohort.
时间窗: Immediately prior to dosing (Day 1, 0hr) to 24 hours post-dose
Blood drawn at Day 7 pre-dose (immediately prior to study drug ingestion) and post-dose at +0.5, +1, +1.5, +2, +2.5, +3, +3.5, +4, +5, +6, +8, +12, +18 and +24 hours post-D7-dose will be assessed for Bendavia plasma concentrations. AUC (0-24hr) will be calculated using validated pharmacokinetic analysis software and mean AUC for Bendavia is defined as the mean of AUC (0-24hr) reported for each subject by cohort.
Ratio of AUC0-24h calculated on Day 7 to AUC0-24h calculated on Day 1 [AUC0-24h (d7)/AUC0-24h (d1)].
时间窗: Immediately prior to dosing (Day 1, 0hr) to 24 hours post-Day 7-dose
Mean AUC (0-24hr) calculated at Day 7 as the ratio of Mean AUC (0-24hr) calculated at Day 1 will be calculated for each Bendavia-treated cohort.
次要结局
- Mean change in concentration of urinary 8-isoprostane (pg/mg creatinine) from pre-dose through to study Day 10 for each cohort.(Prior to dosing (Day 1, 0hr) to Study Day 10)
- Mean change in concentration of urinary 8-hydroxy-2-deoxyguanosine (ng/mg creatinine) from pre-dose through to study Day 10 for each cohort.(Prior to dosing (Day 1, 0hr) to Study Day 10)
- Mean Area Under the Curve (AUC0-24hr) on Day 1 for Bendavia metabolite M1 (hr.ng/ml) in the time from dosing to 24 hours post-D1-dose in each cohort.(Immediately prior to dosing (Day 1,0hr) to 24 hours post-D1-dose)
- Mean Area Under the Curve (AUC0-24hr) on Day 1 for Bendavia metabolite M2 (hr.ng/ml) in the time from dosing to 24 hours post-D1-dose in each cohort.(Immediately prior to dosing (Day 1,0hr) to 24 hours post-D1-dose)
- Mean Area Under the Curve on Day 7 (AUC0-24hr) for Bendavia metabolite M1 (hr.ng/ml) in the time from dosing to 24 hours post-D7-dose in each cohort.(Immediately prior to dosing (Day 7,0hr) to 24 hours post-D7-dose)
- Mean Area Under the Curve on Day 7 (AUC0-24hr) for Bendavia metabolite M2 (hr.ng/ml) in the time from dosing to 24 hours post-D7-dose in each cohort.(Immediately prior to dosing (Day 7,0hr) to 24 hours post-D7-dose)
- Ratio of AUC0-24h for M1 calculated on Day 7 to AUC0-24h calculated on Day 1 [AUC0-24h (d7)/AUC0-24h (d1)].(Immediately prior to dosing (Day 1, 0hr) to 24 hours post-Day 7-dose)
- Ratio of AUC0-24h for M2 calculated on Day 7 to AUC0-24h calculated on Day 1 [AUC0-24h (d7)/AUC0-24h (d1)].(Immediately prior to dosing (Day 1, 0hr) to 24 hours post-Day 7-dose)